Bristol-myers Squibb

This study looked back at medical records to understand how well the medication mavacamten works for people with a specific heart condition called obstructive hypertrophic cardiomyopathy (oHCM) in real-world Canadian clinics. Researchers surveyed doctors and reviewed the charts o…

This study tested new immunotherapy drugs (nivolumab alone and combined with ipilimumab) for people with advanced liver cancer that could not be treated with surgery. It aimed to find safe doses and see if these drugs could shrink tumors and help patients live longer. The trial i…

This large study tested whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy could help people with advanced esophageal cancer live longer or delay cancer growth. It involved 970 adults whose cancer couldn't be removed by surgery and …

This early-stage study tested a new drug called BMS-986288, both by itself and combined with an existing immunotherapy (nivolumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe doses and see if the treat…

This early-phase study tested a new drug called BMS-986315, both by itself and combined with other cancer treatments, in people with advanced solid tumors. The main goals were to check the safety of the drug and see what side effects occurred at different doses. Researchers also …

This early-stage study aimed to find a safe dose for a new cancer drug called BMS-986408. It tested the drug alone and combined with other approved cancer immunotherapies in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was…

This study tested three different drug combinations for men with advanced prostate cancer that had spread and was no longer responding to standard hormone therapy. It aimed to see if adding an immunotherapy drug (nivolumab) to other treatments was safe and could help shrink tumor…

This study tested a new way to give the cancer drug nivolumab—as an injection under the skin instead of a long IV infusion. It involved 139 people with advanced cancers like lung cancer, melanoma, and kidney cancer. The main goal was to see how the body processes the drug when gi…

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) for people with advanced liver cancer that had worsened after standard pill-based treatments. The main goal was to see if the drug combo could shrink tumors and control the cancer. Researche…

This early-stage study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) in children and young adults whose Hodgkin or non-Hodgkin lymphoma had come back or did not respond to standard treatments. The main goals were to find a safe dose and see if the…

This study tested whether using two immunotherapy drugs together (nivolumab and ipilimumab) could help men with advanced prostate cancer that had spread and was no longer responding to standard hormone therapy. It compared this combination against using one of the drugs alone or …

This study monitored the long-term safety of mavacamten, a medication for hypertrophic cardiomyopathy (a condition where the heart muscle thickens). It included 314 adults who had already completed earlier trials testing this drug. Researchers tracked side effects and safety over…

This Phase 3 trial tested whether the drug mavacamten could improve symptoms and exercise capacity in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a genetic heart condition that causes the heart muscle to thicken. The study involved 580 participants…

This study looked at how well the medication mavacamten worked for 163 real patients with obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and blocks blood flow. Researchers at a single US hospital collected information on patients' symp…

This study tested a new targeted drug called farletuzumab ecteribulin (MORAb-202) against standard chemotherapy for women with a specific, hard-to-treat form of ovarian cancer that had stopped responding to platinum-based drugs. The goal was to see if the new drug was safer and m…

This study tested whether adding a third drug (relatlimab) to a standard two-drug treatment (nivolumab and bevacizumab) is safe and more effective for people with untreated advanced liver cancer. It involved 83 participants who were randomly assigned to receive either the three-d…

This study observed 450 people with relapsing multiple sclerosis in Germany who were already prescribed ozanimod (Zeposia) by their doctor. Over three years, it tracked how long patients stayed on the medication, how well it controlled their MS symptoms, and how it affected their…

This study tested the safety and initial effectiveness of a combination of two immunotherapy drugs, nivolumab and ipilimumab, in Chinese patients with advanced solid tumors that had returned or spread after prior treatment. The main goals were to see what side effects occurred an…

This study observed 104 people with relapsing-remitting multiple sclerosis (RRMS) in Italy who switched from their first or second disease-modifying therapy to a newer oral medication called ozanimod. Researchers tracked why patients switched (like side effects or the treatment n…

This large, completed Phase 3 trial tested whether the immunotherapy drug nivolumab could help prevent cancer from returning in patients who had surgery for esophageal or gastroesophageal junction cancer. The study involved 794 patients who had already completed chemotherapy and …

This study compared two different first treatments for Chinese patients with advanced mesothelioma, a cancer of the lung lining that cannot be removed by surgery. Researchers tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better and is sa…

This large, completed Phase 3 trial tested whether immunotherapy drugs (nivolumab with or without ipilimumab), alone or combined with chemotherapy, worked better than standard chemotherapy for people with advanced lung cancer who hadn't had prior treatment. It aimed to see if the…

This study collected real-world information from 112 patients in France with acute myeloid leukemia (AML) who were in remission. It aimed to understand how well an oral maintenance drug called azacitidine works to prevent the cancer from coming back and to describe the patients' …

This study tested a new drug called BMS-813160, given alone or combined with standard chemotherapy and/or an immunotherapy drug (nivolumab), in people with advanced colorectal or pancreatic cancer that had spread. The main goals were to find the safest dose, see how the body proc…

This study tested a new drug called BMS-986322 to see if it could safely reduce the skin plaques and symptoms of moderate-to-severe psoriasis. It involved 109 adults with significant psoriasis coverage and compared the drug's effects to a placebo over 12 weeks. The main goal was …

This study looked back at medical records to see how well a combination of immunotherapy (nivolumab) and chemotherapy worked for Argentinian patients with early-stage, operable lung cancer. The goal was to see if this treatment given before surgery could completely eliminate the …

This study tested the safety and early effectiveness of combining two immunotherapy drugs, nivolumab and daratumumab, for people with multiple myeloma that has returned or stopped responding to standard treatments. It involved about 320 participants with various blood cancers, fo…

This study observed how well patients with advanced non-small cell lung cancer lived after receiving the drug nivolumab in real-world clinics in Greece and Cyprus. It followed 212 patients who had already tried chemotherapy, tracking their survival at 1, 2, and 3 years, their qua…

This study tested whether combining the immunotherapy drug nivolumab with the targeted therapy trametinib, with or without another immunotherapy called ipilimumab, could help control advanced colorectal cancer that had spread and stopped responding to prior treatments. It involve…

This study tested whether an oral medication called deucravacitinib could clear or nearly clear scalp psoriasis better than a placebo. It involved 154 adults with moderate-to-severe scalp psoriasis who had not gotten enough relief from topical creams. Researchers measured how wel…

This study tested the safety and effectiveness of a new immunotherapy drug called BMS-986016 (relatlimab), given alone and in combination with the established drug nivolumab. It involved over 1,400 people with advanced solid tumors that had spread or could not be removed by surge…

This study tested if adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced non-small cell lung cancer that has spread. It involved 719 adults with newly diagnosed stage IV lung c…

This early-stage study tested a new drug called BMS-986249, both by itself and combined with an existing immunotherapy (nivolumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check if the treatments were safe, f…

This study tested the safety and effectiveness of an experimental drug called BMS-986253 when given alongside established immunotherapy drugs (nivolumab with or without ipilimumab). It involved 281 people with advanced, hard-to-treat cancers, including melanoma. The main goals we…

This study tested whether a 30-week course of the drug mavacamten is effective and safe for Japanese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens and obstructs blood flow. The trial involved 38 participants and…

This study tested whether an experimental drug called BMS-986278 could help people with pulmonary fibrosis, a condition that causes scarring in the lungs. 403 participants were randomly assigned to receive either the drug or a placebo for 26 weeks to see if it could slow the decl…

This completed Phase 2 trial tested whether the immunotherapy drug nivolumab, either alone or combined with other cancer drugs, could meaningfully shrink tumors in people with advanced colon cancer that had returned or spread. The study enrolled 385 participants whose tumors had …

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) in Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the safety of the drugs in the body and see early signs of whe…

This early-stage study tested the safety and effects of an experimental drug called BMS-986326 in adults with moderate-to-severe eczema. Researchers gave 64 participants either the drug or a placebo to check for side effects and measure how the drug behaves in the body. The main …

This study tested whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy before lung cancer surgery is better than chemotherapy alone. It involved 505 people with early-stage, operable non-small cell lung cancer. The goal was to see if …

This study tested whether a medication called deucravacitinib could improve the daily life and well-being of people living with plaque psoriasis. It involved 180 adults with moderate-to-severe psoriasis who were already candidates for systemic treatment. Participants were randoml…

This study looked back at the medical records of 418 adults in the US with a lower-risk type of myelodysplastic syndrome (MDS), a bone marrow disorder. The goal was to understand how patients fared in real life when treated with the drug luspatercept for anemia, compared to anoth…

This early-stage study tested a single dose of an experimental antibody drug, BMS-986446, in 46 healthy people. The main goal was to understand how the body processes the drug when given as a shot under the skin versus into a vein, and to check for any side effects. This type of …

This was an early-stage study to check the safety of a new drug called BMS-986460 and see how it moves through the body. It involved 85 healthy adult male volunteers. The research tested different pill versions and measured side effects and drug levels in the blood.

This study measured how a single dose of the cancer drug repotrectinib behaves in people with moderate or severe liver impairment compared to healthy people. Researchers enrolled 18 adults to understand if liver problems change how the drug moves through the body. The goal was to…

This study observed 535 patients in France with advanced non-small cell lung cancer who were already scheduled to receive the drug nivolumab after prior chemotherapy. Its purpose was to collect real-world information on how long the treatment worked, its side effects, and how it …

This study looked back at the real-world experiences of 100 adults with stage III melanoma who received one of two combination drug treatments before surgery. Researchers collected information about the patients, their treatment details, side effects, and long-term outcomes like …

This early-stage study aimed to check the basic safety and how the body processes the experimental drug BMS-986419. It involved 74 healthy volunteers and had two main parts: first, to see what side effects might occur and how the drug moves through the body, and second, to carefu…

This study aimed to monitor the long-term safety of the arthritis drug abatacept after it was approved for use. It tracked over 38,000 people in Denmark with rheumatoid or psoriatic arthritis who were taking the drug. The main goal was to see how often certain cancers, especially…

This study aimed to understand how a new cancer drug, repotrectinib, might change the levels of other common medications in the body. It involved 30 healthy adult volunteers who took repotrectinib alongside several probe drugs, including metformin and omeprazole. The main goal wa…

This study aimed to understand how much of a medication called deucravacitinib, used to treat conditions like psoriasis, passes into breast milk. Researchers measured drug levels in the breast milk and blood of 8 healthy, lactating women after they took a single dose. The goal wa…

This study looked back at medical records to understand how well the drug nivolumab worked in real-world practice for 260 patients in China with advanced stomach cancer. It did not test a new treatment but collected information on how long the cancer was controlled and how patien…

This study tracked over 140,000 people in Sweden with rheumatoid or psoriatic arthritis to see if the drug abatacept affects their risk of developing cancer. Researchers compared cancer rates in people taking abatacept to those taking other standard arthritis medications. The goa…

This study tested how eating food affects the levels of a new drug called Admilparant in the body. It involved 56 healthy volunteers who took the drug either with or without food. The main goal was to measure how much of the drug gets into the bloodstream under these different co…

This study looked back at the medical records of 327 adults with advanced kidney cancer to see how they fared in everyday medical practice. It compared two different combination drug treatments: Nivolumab with Ipilimumab, and Pembrolizumab with Lenvatinib. The goal was to underst…

This study looked back at the medical records of 177 Japanese patients with lower-risk myelodysplastic syndromes (MDS), a type of bone marrow disorder. The goal was to understand what treatments doctors actually use in everyday practice, how well they work, and what the associate…

This early-stage study tested the safety and heart effects of an experimental drug called BMS-986278 in healthy people. The two-part trial involved 42 healthy volunteers to check for side effects and see how the drug moves through the body. Researchers specifically measured if th…

This French study asked cancer patients how satisfied they were with their care when switching from receiving immunotherapy at a hospital to receiving it at home. Researchers surveyed 49 adults with solid tumors who were already approved for home treatment. The goal was to unders…

This early-stage study tested how a single dose of an experimental drug, BMS-986278, is processed by the body in people with different levels of kidney function. It involved 27 participants, including healthy volunteers and people with severe kidney disease or kidney failure requ…